Jazz Pharmaceuticals is a biotechnology business based in the US. Jazz Pharmaceuticals shares (JAZZ) are listed on the NASDAQ and all prices are listed in US Dollars. Jazz Pharmaceuticals employs 2,800 staff and has a trailing 12-month revenue of around $4.2 billion.
Probability of Member receiving $1,000 is a probability of 0.026%; If you don’t make a selection in 45 days, you’ll no longer qualify for the promo. Customer must fund their account with a minimum of $50.00 to qualify. Probability percentage is subject to decrease.
Terms and conditions apply*. For 401k rollovers, existing SoFi IRA members must complete 401k rollovers via this link For SoFi members without a SoFi IRA, a SoFi IRA must first be opened, and 401k rollover must be completed utilizing Capitalize via this link. SoFi and Capitalize will charge no additional fees to process a 401(k) rollover to a SoFi IRA. SoFi is not liable for any costs incurred from the existing 401k provider for rollover. Please check with your 401k provider for any fees or costs associated with the rollover. For IRA contributions, only deposits made via ACH and cash transfer from SoFi Bank accounts are eligible for the match. Click here for the 1% Match terms and conditions.
Trade stocks, ETFs, options, futures and bonds all in one place
$0 commissions on stocks, ETFs and equity options, with low contract fees
Deposit or transfer $10,000+ to earn a 2% Match Bonus. Plus: Get a $100 transfer fee reimbursement on your first brokerage transfer of $2,000 or more. T&C apply.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Jazz Pharmaceuticals stock price (NASDAQ: JAZZ)
Use our graph to track the performance of JAZZ stocks over time.
Is it a good time to buy Jazz Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Is Jazz Pharmaceuticals stock undervalued or overvalued?
Valuing Jazz Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Jazz Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Jazz Pharmaceuticals's PEG ratio
Jazz Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 4.1512. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Jazz Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Jazz Pharmaceuticals's EBITDA
Jazz Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.6 billion.
The EBITDA is a measure of a Jazz Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
Jazz Pharmaceuticals financials
Revenue TTM
$4.2 billion
Operating margin TTM
22.33%
Gross profit TTM
$3.8 billion
Return on assets TTM
4.88%
Return on equity TTM
-9.06%
Profit margin
-8.86%
Book value
$65.18
Market Capitalization
$10.5 billion
TTM: trailing 12 months
Jazz Pharmaceuticals's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Jazz Pharmaceuticals.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Jazz Pharmaceuticals's total ESG risk score
Total ESG risk: 31.66
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Jazz Pharmaceuticals's overall score of 31.66 (as at 12/31/2018) is nothing to write home about – landing it in it in the 51st percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Jazz Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Jazz Pharmaceuticals's environmental score
Environmental score: 4.18/100
Jazz Pharmaceuticals's environmental score of 4.18 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Jazz Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Jazz Pharmaceuticals's social score
Social score: 24.74/100
Jazz Pharmaceuticals's social score of 24.74 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Jazz Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Jazz Pharmaceuticals's governance score
Governance score: 13.74/100
Jazz Pharmaceuticals's governance score puts it squarely in the 8th percentile of companies rated in the same sector. That could suggest that Jazz Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Jazz Pharmaceuticals's controversy score
Controversy score: 1/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Jazz Pharmaceuticals scored a 1 out of 5 for controversy – the highest score possible, reflecting that Jazz Pharmaceuticals has managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
Jazz Pharmaceuticals PLC was last rated for ESG on: 2019-01-01.
Total ESG score
31.66
Total ESG percentile
51.04
Environmental score
4.18
Environmental score percentile
8
Social score
24.74
Social score percentile
8
Governance score
13.74
Governance score percentile
8
Level of controversy
1
Jazz Pharmaceuticals share dividends
We're not expecting Jazz Pharmaceuticals to pay a dividend over the next 12 months.
Jazz Pharmaceuticals share price volatility
Over the last 12 months, Jazz Pharmaceuticals's shares have ranged in value from as little as $95.49 up to $182.99. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Jazz Pharmaceuticals's is 0.332. This would suggest that Jazz Pharmaceuticals's shares are less volatile than average (for this exchange).
Jazz Pharmaceuticals overview
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Defitelio to treat severe veno-occlusive disease; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab in Phase 3 trial to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Epidiolex in Phase 3 trial to treat LGS, DS, and TSC; Suvecaltamide in Phase 2 trial to treat Parkinson's disease tremor; JZP815, a pan-RAF kinase inhibitor in Phase 1 trial that targets components of the mitogen-activated protein kinase; JZP898, a conditionally activated interferon alpha molecule in Phase 1 trial; JZP441 in Phase 1 trial to treat narcolepsy, IH, and other sleep disorders; JZP324, an extended-release low sodium oxybate formulation in Phase 1 trial for patients with sleep disorders; and JZP150 to treat post-traumatic stress disorder. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc. , Sumitomo Pharma Co. , Ltd. , and Werewolf Therapeutics, Inc.
Frequently asked questions
What percentage of Jazz Pharmaceuticals is owned by insiders or institutions? Currently 2.996% of Jazz Pharmaceuticals shares are held by insiders and 101.921% by institutions.How many people work for Jazz Pharmaceuticals? Latest data suggests 2,800 work at Jazz Pharmaceuticals.When does the fiscal year end for Jazz Pharmaceuticals? Jazz Pharmaceuticals's fiscal year ends in December.Where is Jazz Pharmaceuticals based? Jazz Pharmaceuticals's address is: Waterloo Exchange, Dublin, Ireland, D04 E5W7What is Jazz Pharmaceuticals's ISIN number? Jazz Pharmaceuticals's international securities identification number is: USG508711052What is Jazz Pharmaceuticals's CUSIP number? Jazz Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 472147107
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
Advertiser disclosure
Finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which Finder receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. Finder compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
How likely would you be to recommend Finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
